Skip to main content
Contact Us
Subscribe
E-Edition
61°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AnaptysBio, Inc. - Common Stock
(NQ:
ANAB
)
19.58
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 8, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AnaptysBio, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Forecasting The Future: 6 Analyst Projections For AnaptysBio
May 06, 2025
Via
Benzinga
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
May 05, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
April 17, 2025
From
Bright Peak Therapeutics, Inc.
Via
GlobeNewswire
Crude Oil Gains 1%; US Composite PMI Surges In March
March 24, 2025
Via
Benzinga
Exposures
Fossil Fuels
Where AnaptysBio Stands With Analysts
March 04, 2025
Via
Benzinga
Analyst Expectations For AnaptysBio's Future
February 04, 2025
Via
Benzinga
Deep Dive Into AnaptysBio Stock: Analyst Perspectives (9 Ratings)
December 18, 2024
Via
Benzinga
Intuitive Machines Posts Q4 Results, Joins Tesla, AnaptysBio, Coherent And Other Big Stocks Moving Higher On Monday
March 24, 2025
Via
Benzinga
Anaptys Announces Stock Repurchase Plan
March 24, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
UiPath Posts Weak Revenue, Joins SentinelOne, American Eagle And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
March 13, 2025
Via
Benzinga
Key Takeaways From AnaptysBio Analyst Ratings
December 02, 2024
Via
Benzinga
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
March 13, 2025
Via
Benzinga
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 27, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Participation in March Investor Conferences
February 27, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday
February 12, 2025
Via
Benzinga
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment
February 12, 2025
AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.
Via
Investor's Business Daily
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
February 12, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 12, 2025
Via
Benzinga
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
February 12, 2025
Via
Benzinga
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
February 11, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
February 03, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
February 03, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
January 22, 2025
Via
Benzinga
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
January 22, 2025
Via
Benzinga
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 07, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 11, 2024
Via
Benzinga
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data
December 11, 2024
AnaptysBio discontinues ANB032 for atopic dermatitis after a trial failure, refocusing on autoimmune assets with upcoming trial results in 2025-2026.
Via
Benzinga
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
December 11, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Participation in November and December Investor Conferences
November 05, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
November 05, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.